Steroid Hormone Action In Female Reproduction

本项目的重点是肌瘤(肌瘤)，并检查与其发病机制、诊断和/或潜在治疗相关的因素。正在进行的工作旨在评估孕酮反应调节剂CDB2914作为治疗子宫肌瘤的效用。我们之前研究了单次剂量的药物对女性月经周期的影响，结果表明，100或200 mg的剂量分别延迟卵泡期和黄体期的卵泡形成和月经沉淀。最近完成的一项研究表明，与服用安慰剂的妇女相比，服用CDB 2914的妇女在三个月的时间里每天服用10或20毫克的剂量可以减少肌瘤的大小。 一项正在进行的随机双盲临床试验评估CDB 2914在六个月的治疗期间是否有额外的抑制作用，并评估治疗停止后生长抑制的持续时间。我们还使用基因阵列来评估子宫肌瘤的病理生理学。

This project focuses on leiomyomata (fibroids) and examines factors related to their pathogenesis, diagnosis and/or potential treatment. Ongoing work seeks to evaluate the utility of the progesterone response modulator CDB2914 as a treatment of fibroids. We previously investigated the effect of single doses of the agent on the menstrual cycle in women, and showed that doses of 100 or 200 mg retard folliculogenesis and precipitate menses, in the follicular and luteal phase respectively. A recently completed study showed reduction in fibroid size in women receiving CDB 2914 at a daily dose of 10 or 20 mg for three months, as compared to women receiving placebo. An ongoing randomized double-blind clinical trial evaluates whether CDB 2914 has additional inhibitory effect during a six month treatment, and also evaluates the duration of the inhibition of growth after treatment is discontinued. We also are using gene arrays to evaluate the pathophysiology of leiomyomata.